Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 4/20 | 0.48 |
| ▸ | CPT2 | P23786 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890738 | 1.00 | CPT1A (0.48) | CPT1ACPT2USP30MAPTNPSR1 | |
| SCHEMBL3963483 | 0.97 | CPT1A (0.52) | CPT1ACPT2 | |
| SCHEMBL4059432 | 0.97 | CPT1A (0.52) | CPT1ACPT2 | |
| SCHEMBL2894183 | 0.89 | POLB (0.49) | CPT1ACPT2USP30MAPTNPSR1 | |
| SCHEMBL2894182 | 0.89 | POLB (0.49) | CPT1ACPT2USP30MAPTNPSR1 | |
| SCHEMBL8228619 | 0.88 | CPT1A (0.48) | CPT1ACPT2MAPTNPSR1 | |
| SCHEMBL5303450 | 0.86 | CPT1A (0.52) | CPT1ACPT2 | |
| SCHEMBL5303447 | 0.86 | CPT1A (0.52) | CPT1ACPT2 | |
| SCHEMBL5314047 | 0.86 | CPT1A (0.52) | CPT1ACPT2MAPTNPSR1 | |
| SCHEMBL2895923 | 0.86 | CPT1A (0.48) | CPT1ACPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027110-A2 | MGLUR5 MODULATORS III | Astra Zeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| EP-2027120-A2 | MGLUR5 MODULATORS I | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| WO-2007130822-A2 | MGLUR5 MODULATORS III | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | CPT1A 1219/4885CPT2 1082/4885USP30 3125/4885 |
| US-20070259926-A1 | mGluR5 modulators III | GRM5, GRM3, GRIK5 | CPT1A 1746/4885CPT2 1267/4885USP30 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.